{"title":"Multilayer Transcriptomic Analysis Prioritizes RAE1 and SLC25A46 as Alzheimer's Disease Candidate Genes Related to Nucleocytoplasmic Transport and Mitochondrial Homeostasis.","authors":"Tong Liu, Xuhao Chen","doi":"10.1007/s12031-026-02623-9","DOIUrl":"10.1007/s12031-026-02623-9","url":null,"abstract":"<p><p>Regional and cellular heterogeneity complicates transcriptomic candidate prioritization in Alzheimer's disease (AD). We integrated donor-adjusted differential expression, exploratory co-expression analysis, donor-grouped nested machine learning, external evaluation, and single-nucleus and spatial localization. Differential screening used false discovery rate < 0.05 and absolute log2 fold change > 0.10. We also examined functional enrichment, immune context, pseudotime, cell communication, virtual knockout, and exploratory compound screening and docking. Among 173 tissue samples from 63 donors, 356 genes met the screening criteria; 44 of 113 algorithm combinations yielded complete evaluations. RAE1 was downregulated across four discovery regions and both external cohorts, with areas under the receiver operating characteristic curve (AUC) of 0.662 (95% confidence interval 0.429-0.894) and 0.863 (0.693-1.000). The frozen Stepglm[forward] model yielded external AUCs of 0.5154 and 0.8875. SLC25A46 showed opposite discovery and external expression directions. Genome-wide enrichment identified 754 Gene Ontology terms and 62 Kyoto Encyclopedia of Genes and Genomes pathways, including negatively enriched mitochondrial energy and RNA-processing programs. Localization across 61,472 nuclei and 25,293 spatial spots, together with virtual perturbation, defined cellular contexts. R-547, JNJ-7,706,621, and roscovitine provided single-engine docking leads. These findings prioritize RAE1 for nucleocytoplasmic RNA-transport research and SLC25A46 as a context-dependent mitochondrial-homeostasis candidate. The compound results provide leads for target-binding and cellular functional studies.</p>","PeriodicalId":652,"journal":{"name":"Journal of Molecular Neuroscience","volume":"76 4","pages":""},"PeriodicalIF":2.4,"publicationDate":"2026-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149400820","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Identification of Key Fatty acid Metabolism-Related Genes in Vascular Dementia.","authors":"Yanping Zhu, Meng Li, Jing Shi, Ying Chen","doi":"10.1007/s12031-026-02627-5","DOIUrl":"https://doi.org/10.1007/s12031-026-02627-5","url":null,"abstract":"<p><p>Vascular dementia (VaD) is a progressive neurodegenerative disorder characterized by chronic cerebral hypoperfusion and cognitive decline, yet the role of fatty acid metabolism in its pathogenesis remains incompletely understood. Integrated transcriptomic profiling was combined with network-based analysis, weighted gene co-expression network analysis (WGCNA) and machine learning to uncover key fatty acid metabolism-associated molecular features associated with VaD. Single-cell RNA sequencing, intercellular communication inference, and in silico perturbation analyses were applied to define immune-stromal interactions. Potential therapeutic compounds were evaluated using molecular docking and dynamics simulations. We identified three VaD-related fatty acid metabolism genes (VaD-FAMRGs), namely PNPLA3, HSP90AA1, and ALB, which showed consistent diagnostic performance across multiple computational approaches and were associated with lipid metabolism, inflammatory processes, and neurovascular unit dysfunction. Functional enrichment, single-cell RNA sequencing, and in silico gene perturbation analyses provided exploratory insights into the potential associations of these candidate genes with lipid transport, metabolic regulation, synaptic maintenance, and immune-inflammatory processes. Cell-cell communication analysis further revealed activation of the ANGPTL signaling axis, suggesting impaired endothelial-glial interactions driven by lipid metabolic dysregulation. Regulatory network analysis identified key transcriptional and post-transcriptional regulators, including REST, miR-155-5p, and miR-21-5p, which may coordinately modulate VaD-FAMRG expression. Drug repurposing analysis highlighted quercetin as a candidate compound with predicted interactions with all three hub proteins, supported by molecular docking and molecular dynamics simulations. These findings suggest that dysregulated fatty acid metabolism may be associated with the development and progression of VaD through coordinated metabolic, inflammatory, and neurovascular mechanisms. This study provides a systems-level framework for understanding the underlying pathological processes and establishes a theoretical basis for future mechanistic and experimental validation.</p>","PeriodicalId":652,"journal":{"name":"Journal of Molecular Neuroscience","volume":"76 4","pages":""},"PeriodicalIF":2.4,"publicationDate":"2026-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149400819","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hao Huixuan, Wang Ruizhe, Hu Chunrong, Wang Na, Dong Tianwai, Yuan Ludan, Luo Wenzhe, Sui Xiaofang
{"title":"PPARγ at the Nexus of Lipid Metabolism and Neuroinflammation in Alzheimer's Disease: A Longitudinal Multi-omics Analysis.","authors":"Hao Huixuan, Wang Ruizhe, Hu Chunrong, Wang Na, Dong Tianwai, Yuan Ludan, Luo Wenzhe, Sui Xiaofang","doi":"10.1007/s12031-026-02609-7","DOIUrl":"https://doi.org/10.1007/s12031-026-02609-7","url":null,"abstract":"<p><p>Peroxisome proliferator-activated receptor gamma (PPARγ) has emerged as an important regulator linking lipid metabolism and neuroimmune responses in Alzheimer's disease (AD). Increasing evidence suggests that disruption of the lipid-immune axis contributes to disease progression and may underlie the heterogeneous therapeutic responses observed with PPARγ-targeted interventions. Experimental studies indicate that PPARγ activation influences multiple biological processes relevant to AD, including lipid homeostasis, mitochondrial function, inflammatory signaling, and amyloid-β clearance. However, the translation of these findings into consistent clinical benefit remains limited by challenges such as poor blood-brain barrier penetration, systemic adverse effects, and disease stage-dependent therapeutic responses. Recent advances in multi-omics technologies and single-cell transcriptomics have provided new insights into the context-dependent roles of PPARγ in different neural cell populations, highlighting dynamic interactions between lipid metabolism, neuroinflammation, and cellular function throughout AD progression. These findings suggest that PPARγ-associated pathways may represent an important regulatory interface linking metabolic and inflammatory processes, while emphasizing the complexity of their temporal and cell-specific regulation. This review synthesizes current evidence from experimental studies, human multi-omics investigations, and clinical research to provide an updated perspective on the role of PPARγ in coordinating lipid metabolism and neuroinflammation in AD. In addition, we discuss the major translational challenges and emerging therapeutic strategies, including selective PPARγ modulation, improved central nervous system delivery, and precision treatment approaches tailored to disease stage.</p>","PeriodicalId":652,"journal":{"name":"Journal of Molecular Neuroscience","volume":"76 4","pages":""},"PeriodicalIF":2.4,"publicationDate":"2026-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149400821","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Bulk Transcriptomic Inference in Vestibular Schwannoma is Sensitive to Estimated Cell Composition: Cross-Cohort Analysis and Single-Cell Lineage Annotation.","authors":"Mingyang Li, Qingyi Huo, Zhimin Wu, Lixin Huang, Tao Sun, Yibo Zhao, Qingtian Liang, Yunmou Ou, Peixuan Yang, Shunyan Zhu, Yeqing Xie, Chichen Liu, Hui Wang","doi":"10.1007/s12031-026-02624-8","DOIUrl":"https://doi.org/10.1007/s12031-026-02624-8","url":null,"abstract":"<p><p>Bulk transcriptomic differences between vestibular schwannoma (VS) and nerve reflect both gene-expression differences and tissue composition. We evaluated composition sensitivity in GSE39645 (31 VS; nine nerve/Schwann-cell controls), compared a fixed 346-gene set with GSE108524 (27 VS, including 10 sporadic and 17 NF2-related cases; four nerve controls), and used GSE230375 for deconvolution and donor-level pseudobulk. Tumor-only GSE216783 supplied a second reference, while GSE250061 supported descriptive broad-lineage annotation. In the prespecified group-plus-batch model with five MuSiC composition principal components, 326 of 1,410 baseline differentially expressed genes retained both false-discovery rate < 0.05 and absolute log2 fold change > 1 thresholds; 1,084 lost at least one threshold, including 117 with reversed direction, and 405 were adjusted-only threshold calls. The primary design had group variance-inflation factor (VIF) 8.747; 303/500 sample-stratified bootstrap draws exceeded VIF 10 but remained full rank and were retained. Across the fixed 346 genes, direction concordance was 93.4% for all VS, 94.5% for sporadic cases and 93.6% for NF2-related cases. All-VS Pearson correlation was 0.883 (95% percentile interval 0.834-0.897); intervals were conditional on fixed references, annotations and gene set. A 20 + 20 + 20-repeat simulation showed fewer conditional beta-zero composition-only calls but greater expression-only standard errors and root-mean-square coefficient error, with VIF > 10 in 4/20 estimated-MuSiC and 3/20 oracle strong-scenario fits; all fits remained full rank. These analyses quantify model sensitivity; neither broad-lineage assignment nor simulation establishes mechanism, biomarkers or therapeutic targets.</p>","PeriodicalId":652,"journal":{"name":"Journal of Molecular Neuroscience","volume":"76 4","pages":""},"PeriodicalIF":2.4,"publicationDate":"2026-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149384985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Genhui Chen, Ying Ye, Ronghui Zheng, Qian Xie, Fei Li, Wei Yang
{"title":"Integrative Network Pharmacology and Transcriptomic Analysis Prioritizes CCR1 and C5AR1 as Candidate Thromboinflammatory Targets Shared by Panax notoginseng Saponins and Stroke-Relevant Drugs in Ischemic Stroke.","authors":"Genhui Chen, Ying Ye, Ronghui Zheng, Qian Xie, Fei Li, Wei Yang","doi":"10.1007/s12031-026-02625-7","DOIUrl":"10.1007/s12031-026-02625-7","url":null,"abstract":"<p><p>Thromboinflammation is a central pathological process contributing to secondary brain injury after ischemic stroke (IS). Panax notoginseng saponins (PNS) exert pleiotropic anti-inflammatory, antithrombotic, and vascular effects, but the molecular convergence between PNS-associated pharmacology and stroke-relevant conventional agents remains incompletely characterized. We integrated network pharmacology, bulk transcriptomic datasets, single-cell RNA sequencing, regulatory-network analysis, and structure-based molecular docking to prioritize candidate targets shared by PNS and an exploratory screening panel of 16 stroke-relevant pharmacological agents. Predicted drug and PNS targets were intersected with IS-associated differentially expressed genes (DEGs), followed by network analysis, independent cross-dataset expression assessment, gene-set enrichment analysis (GSEA), transcription-factor (TF) prediction with co-expression analysis, myeloid-cell sub-clustering, and GNINA docking. The screening framework yielded 79 shared predicted pharmacological targets and 10 disease-associated candidates: ITK, CDK2, C5AR1, VDR, S1PR2, KIF11, CCR1, FAP, PRKCD, and MAOA. CCR1 and C5AR1 were prioritized because they combined high network connectivity with consistent disease-associated expression across the analyzed datasets and strong links to thromboinflammatory pathways. BATF2 and SPI1 expression positively correlated with both C5AR1 and CCR1 in GSE56267. Myeloid sub-clustering further showed that C5ar1 was broadly distributed across stroke-associated microglial and monocyte/macrophage states, whereas Ccr1 was more restricted to activated inflammatory and infiltrating myeloid populations. GNINA docking of all fourteen network-defined receptor-ligand systems identified five complexes with docking affinity scores between - 8.06 and - 10.94 kcal/mol (ginsenosides Rd and Re at CCR1; notoginsenoside R1, ginsenoside Rg1, and ginsenoside Rd at C5AR1). Collectively, these analyses prioritize CCR1 and C5AR1 as convergent candidate thromboinflammatory nodes shared by PNS-associated and stroke-relevant pharmacological target spaces. The findings are hypothesis-generating and do not establish pharmacological synergy, direct receptor coupling, or causal therapeutic mechanisms.</p>","PeriodicalId":652,"journal":{"name":"Journal of Molecular Neuroscience","volume":"76 4","pages":""},"PeriodicalIF":2.4,"publicationDate":"2026-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149376718","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The Architecture of Nocturnal Fear: A Network Pharmacology Approach to Discover Nightmare-Associated Genes","authors":"Amirsajad Jafari, Shayan Jahanbakhsh, Shima Azadian, Abolfazl Omrani Sarduiyeh, Tara Rajabi","doi":"10.1007/s12031-026-02617-7","DOIUrl":"10.1007/s12031-026-02617-7","url":null,"abstract":"<div><p>Nightmares impose a substantial burden on mental health, yet their molecular determinants remain poorly understood. We employed a network pharmacology approach to identify shared protein targets of structurally diverse nightmare-inducing drugs. This approach revealed an eight-protein interactome: serotonergic (HTR2A, HTR2C, HTR1A, HTR6, HTR7), dopaminergic (DRD2, DRD3), and the potassium channel KCNH2. Protein-protein interaction networks and Gene Ontology analysis identified DRD2, HTR1A, and HTR2A as central hubs. These genes showed enrichment for neurotransmitter receptor activity and synaptic transmission. Multiple validation approaches provided initial, though not definitive, support for specificity. Negative-control drugs with lower nightmare incidence yielded a distinct intersection (ACHE and CHRM2). Permutation analysis confirmed the eight-protein composition was significantly distinct from random expectation (<i>p</i> = 0.0200). Experimental binding data from ChEMBL and IUPHAR/BPS confirmed high-affinity interactions for clozapine (7/8 targets) and partial support for other drugs. Analysis of nightmare-treating drugs revealed six shared proteins (HTR7, HTR2C, HTR1A, KCNH2, DRD3, DRD2). This suggests a “shared pathway perturbation” framework where directionality of modulation may determine clinical outcome. Brain expression data confirmed that all eight proteins are expressed in regions critical for sleep and emotional regulation. This framework offers a mechanistic basis for understanding nightmare susceptibility and identifies potential targets for intervention, while highlighting the need for prospective experimental validation.</p></div>","PeriodicalId":652,"journal":{"name":"Journal of Molecular Neuroscience","volume":"76 4","pages":""},"PeriodicalIF":2.4,"publicationDate":"2026-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149332018","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"KARS1-Related Infantile-Onset Progressive Leukoencephalopathy With or Without Deafness: A Novel Variant and Phenotypic Expansion","authors":"Javad Behroozi, Mehdi khorrami, Arezoo Farhadi, Ahad Ghazavi, Mohammadkazem Seyedabadi, Fahimeh Piryaei","doi":"10.1007/s12031-026-02619-5","DOIUrl":"10.1007/s12031-026-02619-5","url":null,"abstract":"<div><p>Biallelic variants in the <i>KARS1</i> gene, encoding lysyl-tRNA synthetase, are responsible for autosomal recessive disorders such as infantile-onset progressive leukoencephalopathy with or without deafness (LEPID; OMIM #619147) and nonsyndromic hearing loss (DFNB89). Common features of LEPID include sensorineural hearing loss, developmental delay, and leukoencephalopathy, but dysmorphic facial features and cardiac anomalies are not commonly reported. This study presents the first documented LEPID case in Iran, expanding the phenotypic and genetic spectrum of <i>KARS1</i>-related disorders. Whole exome sequencing (WES) was performed on a two-year-old Iranian boy from non-consanguineous parents, without a positive history of any neurologic conditions. Identified variants were validated by Sanger sequencing, with familial segregation analysis. Moreover, a literature review of 41 <i>KARS1</i>-related cases was conducted to compare clinical and genetic findings. WES identified two compound heterozygous <i>KARS1</i> variants (NM_005548.3): c.959G > A (p.Arg320His) and c.2T > C (p.Met1Thr), previously reported and novel, respectively, both of which were classified as likely pathogenic according to the American College of Medical Genetics and Genomics criteria. The patient exhibited typical LEPID features (sensorineural hearing loss, developmental delay, seizures, leukoencephalopathy) alongside unprecedented dysmorphic facial features (e.g., synophrys, pointed triangular chin) and cardiac anomalies (pulmonary stenosis, atrial septal defect). Literature review confirmed these dysmorphic features as novel, absent in prior cases, with cardiac involvement in a limited number of patients. This study highlights a novel <i>KARS1</i> variant and an expanded phenotypic spectrum of LEPID, emphasizing the role of WES in diagnosing rare disorders even in non-consanguineous marriages. These findings advocate for broader phenotypic recognition and functional studies to elucidate <i>KARS1’s</i> role in neurodevelopmental, craniofacial, and cardiac abnormalities.</p></div>","PeriodicalId":652,"journal":{"name":"Journal of Molecular Neuroscience","volume":"76 4","pages":""},"PeriodicalIF":2.4,"publicationDate":"2026-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149316967","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"NMN Ameliorates STXBP1-R292C Variant-mediated Developmental and Motor Dysfunction: Molecular Docking and Functional Studies","authors":"Hila Ben-Moshe, Joseph Levine, Efrat Ben-Zeev, Noa Bielopolski, Shane Wald-Altman, Trisha Brock, Anastasia Levichev, Ella Gordon, Sagi Gidali, Bruria Ben-Zeev, Illana Gozes","doi":"10.1007/s12031-026-02612-y","DOIUrl":"10.1007/s12031-026-02612-y","url":null,"abstract":"<div><p>STXBP1-related disorders (STXBP1-RD) are severe neurodevelopmental conditions associated with synaptic dysfunction, presenting an unmet medical need. P.Arg292Cys (R292C) variant is predicted to alter protein stability and affect interactions involved in synaptic vesicle fusion. This study aimed to screen for interactions between STXBP1-R292C and FDA-approved drugs and natural compounds using in silico and in vivo methods to better understand STXBP1-RD molecular defects. We employed computational structural modeling of STXBP1-R292C, screening and ranking transiently interacting drugs, followed by in vivo phenotypic assessment in a humanized STXBP1-R292C <i>Caenorhabditis elegans (C. elegans)</i> model, and longitudinal clinical observation in a single individual carrying the R292C variant. STXBP1-interacting FDA-approved drugs and natural compounds were identified using in silico analysis based on predicted structural effects. <i>C. elegans</i> locomotion features were quantified using standardized assays. Clinical outcomes were assessed using Vineland-III over 25 months. Computational modeling identified β-nicotinamide mononucleotide (NMN) as one of the lead compounds predicted to transiently stabilize the STXBP1-R292C. We further discovered that NMN was unstable in the R292C mutant STXBP1 pocket and diffused from it, whereas its metabolite the essential coenzyme, nicotinamide adenine dinucleotide (NAD<sup>+</sup>) remained stable at the binding site throughout the structural simulation. In the <i>C. elegans</i> model, NMN exposure partially, but significantly, modulated locomotion phenotypes toward a wild-type (WT) profile. Vineland-III assessment of a child (2–4 years old) with STXBP1-RD and motor delays showed improved motor domain scores, while other developmental domains displayed limited changes. Our study revealed an association between STXBP1-R292C/STXBP1 and NMN/NAD<sup>+</sup> as a lead molecule. At the organismal level, NMN treatment ameliorated motor defects in humanized STXBP1-R292C <i>C. elegans</i>. Lastly, 2-year observations in a child carrying the same mutation suggested an NMN effect on the motor domain, toward a future well-designed clinical trial.</p></div>","PeriodicalId":652,"journal":{"name":"Journal of Molecular Neuroscience","volume":"76 4","pages":""},"PeriodicalIF":2.4,"publicationDate":"2026-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149234896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The mechanism of Phosphatidylethanolamine-Binding Protein 1 in Neuro-Related Diseases","authors":"Yizhe Mu, Xingyu Li, Yuhang Yuan, Fangyu Meng, Hongyu Xiong, Zice Zhou, Lingqiao Wu, Xiaopeng Yang, Shaoyang Zhang, Ceshi Chen, Yuan Zhang","doi":"10.1007/s12031-026-02616-8","DOIUrl":"10.1007/s12031-026-02616-8","url":null,"abstract":"<div><p>Phosphatidylethanolamine-Binding Protein 1 (PEBP1), also known as Raf Kinase Inhibitory Protein (RKIP), is a widely expressed, highly conserved multifunctional signaling regulator that governs the activity of central signaling pathways including Mitogen-Activated Protein Kinase (MAPK), Nuclear Factor-κB (NF-κB) and G Protein-Coupled Receptors (GPCRs). We note that recent research has uncovered its role as a critical ferroptosis regulator, showing remarkably specific expression and function across different diseases. Here we systematically review the structure and function of PEBP1, focusing on its core mechanisms as a molecular hub in various neurological disorders. We also systematically integrate PEBP1’s multiple roles across these disorders and explain its key position within neuropathological networks by coupling classical signaling pathways with the ferroptosis program. We further examine intervention strategies targeting its functional states and protein interaction networks, and then discuss its clinical translational potential as a therapeutic target, hoping to provide insights for investigations into disease-related mechanisms and the development of therapeutic strategies.</p><p>Clinical trial number: not applicable.</p></div>","PeriodicalId":652,"journal":{"name":"Journal of Molecular Neuroscience","volume":"76 4","pages":""},"PeriodicalIF":2.4,"publicationDate":"2026-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149234820","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Cannabidiol Regulates Amyloid-β Plaque Deposition and Astrogliosis in the 5xFAD Transgenic Mouse Model","authors":"Sarah Ng, Rishi K. Somvanshi, Ujendra Kumar","doi":"10.1007/s12031-026-02613-x","DOIUrl":"10.1007/s12031-026-02613-x","url":null,"abstract":"<div><p>Alzheimer’s Disease (AD) is marked by the accumulation of amyloid-beta (Aβ) plaques, neurofibrillary tangles, and neuroinflammation. Cannabidiol (CBD), the major non-psychoactive compound of Cannabis, has demonstrated significant pharmacological potential for the treatment of AD. CBD is known to act on various receptors, including cannabinoid receptor 1 (CB1R) and 2 (CB2R), and peroxisome proliferator activated receptor γ (PPARγ). However, the precise changes in receptor expression in AD, as well as following CBD treatment, remain unclear and inconsistent in literature. To address this, we performed immunohistochemistry and immunoblotting in AD-compromised brain regions, specifically the cortex and the hippocampus. In 5xFAD transgenic (TG) mice, we noted strong deposition of Aβ plaques and glial fibrillary acidic protein (GFAP)- positive astrocytes. However, following CBD treatment, Aβ plaque burden and GFAP accumulation were significantly reduced. We observed increased CB1R expression in the cortex of TG mice, in comparison to age-matched wild-type control mice. CB2R expression changes were insignificant between the two groups, however, following CBD treatment, CB2R expression was significantly increased. Interestingly, we demonstrated PPARγ co-expressed with Aβ plaques in TG mice, and following CBD treatment, PPARγ co-expression increased. Lastly, we demonstrated dysregulations of the PI3K signaling pathway observed in TG mice was ameliorated with CBD treatment. In this study, we attributed the effects of CBD on AD-related biomarkers, particularly decreased Aβ plaque load and neuroinflammation, to the alterations in CB2R and PPARγ expression.</p></div>","PeriodicalId":652,"journal":{"name":"Journal of Molecular Neuroscience","volume":"76 4","pages":""},"PeriodicalIF":2.4,"publicationDate":"2026-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149234819","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}